Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever

Kallinich, Tilmann; Wittkowski, Helmut; Keitzer, R.; Roth, Johannes; Foell, Dirk

doi:10.1136/ard.2009.114363

Cited by 86 publications

(85 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[27][28][29] Also in a study of Isoyama et al s100a12 was four times higher in level 5 CKD 5 patients than in controls and increased with increasing hsCRP. 25 Likewise, in the current study, S100A12 and CRP were higher in PD patients when compared with controls.…”

Section: Discussionmentioning

confidence: 99%

Do elevated plasma S100A12 levels predict atherosclerosis in peritoneal dialysis patients?

et al. 2015

View full text Add to dashboard Cite

Aim: Atherosclerotic cardiovascular disease is one of the major causes of mortality and morbidity in peritoneal dialysis (PD) patients. S100A12 is an endogenous receptor ligand of advanced glycation end-products. It was shown to contribute to the development of atherosclerosis in animal models. The aim of this study was to evaluate the relationship between S100A12 levels and carotid atherosclerosis in PD patients. Methods: A cross-sectional study was performed in 56 PD patients and 20 control subjects. Plasma S100A12 levels were measured from all participants beside routine laboratory evaluation. All subjects underwent high-resolution B-mode ultrasonography to determine carotid intima media thickness (CIMT). S100A12 levels were compared between patient and control groups. Correlation analyses of S100A12 with other laboratory values and CIMT were also performed. Results: Plasma S100A12 levels were higher in PD patients compared with control subjects (129.5 ± 167.2 ng/mL vs. 48.5 ± 30.3 ng/mL, respectively, p50.001). In the patient group, CIMT was found to be positively correlated with age (r ¼ 0.354; p ¼ 0.007), CRP level (r ¼ 0.269; p ¼ 0.045), and S100A12 (r ¼ 0.293; p ¼ 0.028) level while it was found to be negatively correlated with hemoglobin concentration (r ¼ À0.264; p ¼ 0.049). In the linear regression analysis, the model, including CRP, S100A12, age, and Hgb, was found to be significant (F: 4.177, p: 0.005). When the parameters are analyzed age and S100A12 were found to be independent determinants of CIMT ( ¼ 0.308, p ¼ 0.018 and ¼ 0.248, p ¼ 0.049, respectively). Conclusions: This study suggests that an elevated plasma S100A12 level was closely associated with atherosclerosis. With aging elevated plasma S100A12 may show a powerful proatherogenic potential in patients undergoing PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Do elevated plasma S100A12 levels predict atherosclerosis in peritoneal dialysis patients?

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Bu gen başlıca bir protein olan interlökin 1-β üretimini baskılayarak lökositlerin seröz zarlara göçünü önleyen pirin proteinini kodlamaktadır [1][2][3]. MEFV geni mutasyonu sonucu bu baskılayıcı mekanizma ortadan kalkınca proinflamatuar reaksiyonlar sürekli aktif hale gelir [4]. Hastalığın klinik görünümü, başlatıcı bir dış etken olmaksızın, düzensiz aralıklarla gelen ve kendini sınırlayan ateş atakları ve beraberindeki serözit bulguları ile seyreder.…”

Section: Introductionunclassified

“…Hastalığın klinik görünümü, başlatıcı bir dış etken olmaksızın, düzensiz aralıklarla gelen ve kendini sınırlayan ateş atakları ve beraberindeki serözit bulguları ile seyreder. Lokal inflamatuar reaksiyon şeklindeki serözit başlıca nötrofilerin masif göçü ile gerçekleştirilir [4].…”

Section: Introductionunclassified

“…Amiloid birçok organda birikmekle birlikte sıklıkla morbidite ve mortaliteye neden olan renal amiloidozdur. Profilaktik olarak sürekli kolşisin kullanımının ateş ve serözit atakları ile amiloid gelişimini önlediği bilinmektedir [3,4]. Ancak yeterli kolşisin tedavisine rağmen bazı hastalarda değişen derecelerde subklinik inflamasyonun devam ettiği bildirilmiştir [5][6][7][8].…”

Section: Introductionunclassified

See 1 more Smart Citation

Comparison of acute phase response during attack and attack-free period in children with Familial Mediterranean Fever

Çakmak

Ece²,

Kelekçi³

et al. 2013

J Clin Exp Invest

View full text Add to dashboard Cite

Objective: The aim of this study was to compare acute phase reactant (AFR) levels at attack period and attackfree period under colchicine treatment in children with Familial Mediterranean Fever (FMF). Methods:The diagnosis of FMF was done based on clinical criteria and patients were prospectively followed up for average of 1.2 years. Symptom-onset age, age at diagnosis, clinical symptoms and features of FMF attacks were recorded. MEFV gene mutations were detected by reverse hybridization (strip assay) method. Peripheral blood leukocyte count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and blood fibrinogen levels were measured by standard methods, both at attack period and during attack-free period.Results: Totally 105 (55 girls, 50 boys) children with FMF were included. The mean age was 8.9±3.2 years, mean symptom onset age was 5.9 years and mean age at diagnosis was 8.1 years. MEFV gene mutations were as follows: E148Q (29.2%), M694V (24.8%), R761H (15.3%) and V726A (13.1%). The mean AFR values were over normal values in attack period and there was at least one high AFR level in 80.0% of patients. In attack-free period, although the mean values of all AFRs were within normal limits, 31.4% of patients had at least one high AFR level. Conclusion:Based on these data, one-third of FMF children had a high AFR level, which may be a marker of subclinical inflammation. In children with continuous inflammation during attack-free period, a new anti-inflammatory drug additional to colchicine can be considered in order to prevent complications of chronic inflammation. J Clin Exp Invest 2013; 4 (2): 213-218Key words: Familial Mediterranean Fever, acute phase reactants, children, attack period, attack-free period ÖZET Amaç: Bu çalışmanın amacı Ailesel Akdeniz Ateşi (AAA) bulunan çocuklarda akut faz belirteci (AFB) düzeylerinin atak dönemi ve kolşisin tedavisi altında ataksız dönemde-ki düzeylerini karşılaştırmaktır.Yöntemler: Klinik kriterlere göre AAA tanısı kondu ve tüm hastalar prospektif olarak ortalama 1,2 yıl süreyle izlendi. Hastaların semptom başlama yaşı, tanı yaşı, klinik semptomlar ve AAA atağına ait bilgiler kaydedildi. MEFV gen mutasyonları test hibridizasyon (strip Assay) yöntemi ile çalışıldı. Akut faz belirteci olarak periferik kan lökosit sayısı, eritrosit çökme hızı (EÇH), serum C-reaktif protein (CRP) ve fibrinojen düzeyleri hem AAA atağı sırasında hem de ataklar arası dönemde standart yöntemlerle öl-çüldü.Bulgular: Çalışmaya 105 (55 kız, 50 erkek) AAA'lı çocuk alındı. Hastaların yaş ortalaması 8,9±3,2 yıl, ortalama semptom başlangıç yaşı 5,9 yıl ve ortalama tanı yaşı 8,1 yıl idi. MEFV gen mutasyonu olarak azalan sıklık sırasına göre; E148Q (%29,2), M694V (%24,8), R761H (%15,3) ve V726A (%13,1) oranlarında saptandı. Atak döneminde hastaların ortalama AFB düzeyleri normal değerlerin üs-tünde olup, %80'inde en az bir AFB yüksek bulundu. Atak dışı dönemde ise tüm AFB ortalama değerleri normal sı-nırlar içinde olmakla birlikte, %31,4'ünde en az bir AFB düzeyi normalden yüksek bulund...

show abstract

“…As more specific reagents for individual S100 proteins are being generated, their potential diagnostic and prognostic usage will increase substantially. Very recently, several groups contributed to the current debate on the use of extracellular S100 proteins in plasma, urine and other compartments as biomarkers in a panoply of common and rare disorders, e.g., in patients with familial Mediterranean fever (S100A12; Kallinich et al 2010), inflammatory joint diseases (S100A8, S100A9 and S100A12; Baillet et al 2010), mood disorders (S100B; Schroeter et al 2010), traumatic head injury (S100B; Hallén et al 2010), bladder adenocarcinoma (S100P; Raspollini et al 2010) and lung squamous cell carcinoma (S100A4; Tsuna et al 2009). This continuing debate also highlights the complex levels of both cell and tissue regulatory specificity and functional diversity of the S100 proteins.…”

mentioning

confidence: 99%

S100 proteins in health and disease

Pietzsch

2010

Amino Acids

View full text Add to dashboard Cite

Neutrophil-derived S100A12 as novel biomarker of inflammation in familial Mediterranean fever

Abstract: S100A12 is a valuable biomarker for monitoring disease activity, inflammation and response to colchicine treatment in patients with FMF. It might even be more sensitive in detecting subclinical inflammation than other available indicators.

Cited by 86 publications

References 32 publications

Do elevated plasma S100A12 levels predict atherosclerosis in peritoneal dialysis patients?

Do elevated plasma S100A12 levels predict atherosclerosis in peritoneal dialysis patients?

Comparison of acute phase response during attack and attack-free period in children with Familial Mediterranean Fever

S100 proteins in health and disease

Contact Info

Product

Resources

About